Acute symptomatic seizures

 

Definitions

   Seizures occurring:

o   At the time of a systemic insult OR

o   In close temporal relationship to an acute brain insult

-   Within 7 days of stroke, TBI, anoxic encephalopathy, intracranial surgery

-   First identification of subdural haemorrhage

-   During presence of active infection

-   During active phase of MS relapse or autoimmune disease

-   Within 24 hours of metabolic derangements including

   drug and alcohol withdrawal

   seizure provoking medications

 

ILAE proposed cut-offs for metabolic derangements causing seizures

   Glucose <2 or >25

   Sodium <115

   Calcium <1.2

   Magnesium <0.3

   Creatinine >884umol/L

 

 

Epidemiology

   40% of patients with seizures

   50-70% of status epilepticus episodes

   Lifetime risk Male vs female – 5% vs 2.7%

   In an 80yo person the lifetime risk of acute symptomatic seizures in 3.6%

   Highest incidence in first year of life and then in the elderly

   High risk of mortality in first 30 days (up to 20%) – this is 8.9x higher than after unprovoked seizure

o   The increased mortality is related to underlying conditions

 

Stroke

After matching for stroke severity etc worse outsomes if seizures ocure – mortality (27% vs 14%) and mRS worse

 

 

Risk of recurrence

   Overall 18.7% risk of seizure recurrence, however a single figure is not useful, given significant variation depending on aetiology (see graph below).

   Prediction of risk

A graph of a graph showing a number of cells

AI-generated content may be incorrect.l

Treatment:

Treatment can be at different times for different reasons

   Primary prevention prior to insult (i.e before neuro-surgery)

   Prophylactic during actue insult to prevent acute seizures

   Prophyactic during acute phase to prevent long term epilepsy

   Post acute seizure to prevent recurrence

Primary prevention evidence

·       Reduced acute symptomatic seizures, but does not reduce late seizures/remote symptomatic epilepsy

·       In stroke limited studies, no clear benefit

·       Some evidence of poorer rehabilitation outcomes in patients treated with ASM, effect also present with newer ASM